 CAMBRIDGE, Mass.--BUSINESS WIRE--VBI Vaccines Inc. Nasdaq:VBIV VBI, a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced positive Phase 1 data from its Phase 12 trial of the first of its enveloped virus-like particle eVLP COVID-19 vaccine candidates, VBI-2902a, in healthy adults age 18-54 years of age. The 5μg dose of VBI-2902a, which expresses an optimized SARS-CoV-2 spike antigen and is adjuvanted with alumin 